AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30045729 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Sanitation Blocks (CSB)
Number of subjects: 96
Study 30045729 — intervention group
Group type: COMPARATOR
Intervention: Traditional Latrine (TL)
Number of subjects: 96
Study 30045729 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved shared sanitation facilities (SL and CSB)
Number of subjects: 96
Study 30045812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered off maintenance immunosuppression
Number of subjects: 44
Study 30045812 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH activity index over two
Number of subjects: 44
Study 30045812 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation based on activity index and duration of systemic lupus erythematosus
Number of subjects: 44
Study 30045838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine (10 μg/kg) administered intravenously on the last day of hypomethylating agent (HMA) infusion (azacitidine or decitabine) in 4-week cycles.
Number of subjects: 53
Study 30045838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine combined with HMAs.
Number of subjects: 53
Study 30045932 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-803, a novel recombinant IL15 complex
Number of subjects: 0
Study 30045949 — intervention group
Group type: EXPERIMENTAL
Intervention: Versi
Number of subjects: 4
Study 30045949 — intervention group
Group type: EXPERIMENTAL
Intervention: Embotrap
Number of subjects: 4
Study 30045949 — intervention group
Group type: COMPARATOR
Intervention: Solitaire
Number of subjects: 4
Study 30045949 — intervention group
Group type: COMPARATOR
Intervention: Trevo
Number of subjects: 4
Study 30046225 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday regimen of amifostine
Number of subjects: 187
Study 30046225 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-other-day regimen of amifostine
Number of subjects: 187
Study 30046225 — intervention group
Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 187
Study 30046307 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 administration
Number of subjects: 0
Study 30046464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid multifocal IOLs (OptiVis)
Number of subjects: 160
Study 30046464 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 160
Study 30046464 — intervention group
Group type: COMPARATOR
Intervention: Refractive multifocal IOLs
Number of subjects: 160
Study 30046708 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (up to 5 g as two consecutive intravenous infusions over 5-10 minutes each)
Number of subjects: 5
Study 30046708 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 5
Study 30046714 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin gel (1120 IU/100 g), administered 2-3 times daily for 16 days
Number of subjects: 0
Study 30046714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30046762 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 30046988 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF) for 4 weeks
Number of subjects: 90
Study 30046988 — intervention group
Group type: COMPARATOR
Intervention: Current diet (control group)
Number of subjects: 90
Study 30048002 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH) vitamin D metabolite
Number of subjects: 160
Study 30048002 — intervention group
Group type: EXPERIMENTAL
Intervention: 25OHD vitamin D metabolite
Number of subjects: 160
Study 30048496 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to a sexual partner within a month of diagnosis
Number of subjects: 40
Study 30048496 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge or strong suspicion about the source of infection
Number of subjects: 40
Study 30048496 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted partner notification, individual and couples counseling, and couples HIV testing
Number of subjects: 40
Study 30048507 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure (MFM) assessment
Number of subjects: 81
Study 30048507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 81
Study 30048507 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength assessment
Number of subjects: 81
Study 30048507 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroneuromyography
Number of subjects: 81
Study 30048507 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle imaging
Number of subjects: 81
Study 30048507 — intervention group
Group type: EXPERIMENTAL
Intervention: Workspace volume assessment
Number of subjects: 81
Study 30049272 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy (BA)
Number of subjects: 242
Study 30049272 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 242
Study 30049699 — intervention group
Group type: EXPERIMENTAL
Intervention: ReTrain intervention
Number of subjects: 45
Study 30049701 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents (aged 14-17 years)
Number of subjects: 0
Study 30049701 — intervention group
Group type: COMPARATOR
Intervention: Young adults (aged 20-29 years)
Number of subjects: 0
Study 30049743 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole monotherapy
Number of subjects: 0
Study 30049743 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone monotherapy
Number of subjects: 0
Study 30049743 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30050047 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA levels in the dACC
Number of subjects: 229
Study 30050047 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 229
Study 30050047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis of GABA levels
Number of subjects: 229
Study 30050047 — intervention group
Group type: EXPERIMENTAL
Intervention: Other metabolites (creatine)
Number of subjects: 229
Study 30050047 — intervention group
Group type: COMPARATOR
Intervention: Frontal white matter control region
Number of subjects: 229
Study 30050529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY)
Number of subjects: 15
Study 30050529 — intervention group
Group type: COMPARATOR
Intervention: Natalizumab (NAT)
Number of subjects: 15
Study 30050529 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT and FTY
Number of subjects: 15
Study 30050529 — intervention group
Group type: COMPARATOR
Intervention: NAT
Number of subjects: 15
Study 30050529 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY
Number of subjects: 15
Study 30051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient management and treatment improvements
Number of subjects: 0
Study 30051292 — intervention group
Group type: EXPERIMENTAL
Intervention: International registry data
Number of subjects: 0
Study 30051292 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis and prognosis biomarkers
Number of subjects: 0
Study 30051298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of a water-based, peelable nail polish
Number of subjects: 102
Study 30051298 — intervention group
Group type: COMPARATOR
Intervention: 5% amorolfine nail lacquer (weekly application)
Number of subjects: 102
Study 30051298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 102
Study 30051724 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin for cellulitis
Number of subjects: 136
Study 30051724 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline procalcitonin levels
Number of subjects: 136
Study 30051724 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 136
Study 30052057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 48
Study 30052269 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (300 mg single dose) in moderate hepatic impairment (n = 8)
Number of subjects: 16
Study 30052269 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib (300 mg single dose) in severe hepatic impairment (n = 8)
Number of subjects: 16
Study 30052269 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (n = 12)
Number of subjects: 16
Study 30052304 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 Left Ventricular Assist System
Number of subjects: 50
Study 30053006 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg apatinib once a day (q.d.)
Number of subjects: 20
Study 30053006 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg apatinib once a day (q.d.)
Number of subjects: 20
Study 30053231 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative AKI patients
Number of subjects: 86
Study 30053231 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without AKI but with positive post-operative CCA biomarkers
Number of subjects: 86
Study 30053231 — intervention group
Group type: COMPARATOR
Intervention: Patients with neither clinical AKI nor positive biomarkers
Number of subjects: 86
Study 30053231 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed new CKD
Number of subjects: 86
Study 30053671 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 875
Study 30053671 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 875
Study 30053671 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (letrozole or fulvestrant)
Number of subjects: 875
Study 30053825 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 20
Study 30053861 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban greening interventions (tree and flower planting, artificial tree decorations)
Number of subjects: 0
Study 30053861 — intervention group
Group type: COMPARATOR
Intervention: Matched comparison sites (no interventions)
Number of subjects: 0
Study 30053861 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban greening interventions
Number of subjects: 0
Study 30053905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg BID for 6 weeks followed by HD IL-2 (600,000 IU/kg every 8 hours on days 1-5 and days 15-19)
Number of subjects: 53
Study 30053905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib for 7-18 weeks followed by HD IL-2 (600,000 IU/kg every 8 hours on days 1-5 and days 15-19)
Number of subjects: 53
Study 30053915 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex as determinants of humoral immunity
Number of subjects: 1000
Study 30053915 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in the HLA class II region
Number of subjects: 1000
Study 30053915 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgA levels
Number of subjects: 1000
Study 30053953 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity (number of steps per day)
Number of subjects: 202
Study 30053953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min sit to stand test (STS)
Number of subjects: 202
Study 30053953 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 min walking test (6MWT)
Number of subjects: 202
Study 30054122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg every 4 weeks for 3 months as an add-on to glucocorticoids (prednisone starting at 0.7 mg/kg/day)
Number of subjects: 20
Study 30054122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 20
Study 30054623 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Elaboration Training (RET/M-RET)
Number of subjects: 26
Study 30054698 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1R PET/CT
Number of subjects: 52
Study 30054698 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 52
Study 30054698 — intervention group
Group type: EXPERIMENTAL
Intervention: study-MRI
Number of subjects: 52
Study 30054698 — intervention group
Group type: COMPARATOR
Intervention: prior external CT/MRI
Number of subjects: 52
Study 30054977 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued Appropriate Medical Therapy (CAMT)
Number of subjects: 202
Study 30054977 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus Surgery (ESS)
Number of subjects: 202
Study 30055091 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 69
Study 30055091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 69
Study 30055091 — intervention group
Group type: COMPARATOR
Intervention: Antimalarial agents
Number of subjects: 69
Study 30055562 — intervention group
Group type: EXPERIMENTAL
Intervention: SEVO+ (sevoflurane with additional BIS and TOF monitoring)
Number of subjects: 120
Study 30055562 — intervention group
Group type: COMPARATOR
Intervention: SEVO (sevoflurane without additional monitoring)
Number of subjects: 120
Study 30055562 — intervention group
Group type: EXPERIMENTAL
Intervention: PROP+ (propofol with additional BIS and TOF monitoring)
Number of subjects: 120
Study 30055562 — intervention group
Group type: COMPARATOR
Intervention: PROP (propofol without additional monitoring)
Number of subjects: 120
Study 30055573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal challenge with wild-type influenza A/H1N1pdm virus
Number of subjects: 65
Study 30055589 — intervention group
Group type: EXPERIMENTAL
Intervention: FT4 at admittance
Number of subjects: 539
Study 30055589 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH at admittance
Number of subjects: 539
Study 30055589 — intervention group
Group type: EXPERIMENTAL
Intervention: FT4 from admittance to discharge
Number of subjects: 539
Study 30055589 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH from admittance to discharge
Number of subjects: 539
Study 30055589 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH levels in female patients with SUD
Number of subjects: 539
Study 30055589 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FT4 and TSH levels between diagnostic groups
Number of subjects: 539
Study 30055608 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbations with pneumonic infiltrates
Number of subjects: 127
Study 30055608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial detection in pneumonic group
Number of subjects: 127
Study 30055608 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral detection and sputum microbiota
Number of subjects: 127
Study 30055613 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrotics
Number of subjects: 525
Study 30055613 — intervention group
Group type: COMPARATOR
Intervention: Steroids, immunosuppressants, N-Acetylcysteine
Number of subjects: 525
Study 30055633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active yoga breathing techniques
Number of subjects: 33
Study 30055633 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive yoga breathing techniques (pranayama)
Number of subjects: 33
Study 30055633 — intervention group
Group type: COMPARATOR
Intervention: Control (standard pharmacological treatment)
Number of subjects: 33
Study 30055634 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored for ≤ 7 days
Number of subjects: 1538
Study 30055634 — intervention group
Group type: COMPARATOR
Intervention: Standard-issue RBCs (oldest in inventory)
Number of subjects: 1538
Study 30055804 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy in patients <70 years
Number of subjects: 1329
Study 30055804 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy in patients ≥70 years
Number of subjects: 1329
Study 30055804 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy
Number of subjects: 1329
Study 30055824 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of inhaled nemiralisib (100 μg)
Number of subjects: 22
Study 30055824 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of inhaled nemiralisib (200 μg)
Number of subjects: 22
Study 30055824 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat dose of inhaled nemiralisib (200 μg for 10 days)
Number of subjects: 22
Study 30055824 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of inhaled nemiralisib (200 μg) with charcoal block
Number of subjects: 22
Study 30055824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30055837 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping for JS and complete age-appropriate ophthalmic examinations
Number of subjects: 99
Study 30055837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ptosis surgery
Number of subjects: 99
Study 30056094 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 24
Study 30056094 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 24
Study 30056385 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention physiotherapy (treatment within 2 weeks after randomisation)
Number of subjects: 80
Study 30056385 — intervention group
Group type: COMPARATOR
Intervention: Usual care (treatment 6 weeks postrandomisation)
Number of subjects: 80
Study 30056385 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention physiotherapy
Number of subjects: 80
Study 30056385 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 30056391 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis plus haemoperfusion (HD/HP)
Number of subjects: 1364
Study 30056391 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis alone (HD)
Number of subjects: 1364
Study 30057012 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan (vasopressin V1A/V2 receptor antagonist)
Number of subjects: 0
Study 30057012 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30057766 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors for HFpEF
Number of subjects: 3847
Study 30057766 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors for HFrEF
Number of subjects: 3847
Study 30057766 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors for VHF
Number of subjects: 3847
Study 30057766 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to heart failure diagnosis
Number of subjects: 3847
Study 30057766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure types diagnosed
Number of subjects: 3847
Study 30057787 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 102
Study 30057787 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight children
Number of subjects: 102
Study 30057787 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy children
Number of subjects: 102
Study 30057798 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass radio campaign promoting health-seeking behaviours
Number of subjects: 620000
Study 30057802 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized toric intraocular lens (FIL 611 T, Soleko, Rome, Italy) implantation
Number of subjects: 10
Study 30058068 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progesterone and CA125
Number of subjects: 100
Study 30058068 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler indices (uterine artery/corpus luteum resistance index and pulsatility index)
Number of subjects: 100
Study 30058349 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased copeptin levels in plasma
Number of subjects: 65
Study 30058572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus chemotherapy (R-chemo)
Number of subjects: 314
Study 30059396 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Surgical Safety Checklist compliance
Number of subjects: 859
Study 30059932 — intervention group
Group type: EXPERIMENTAL
Intervention: Wind instruments (bassoon, clarinet, oboe, saxophone)
Number of subjects: 40
Study 30059932 — intervention group
Group type: EXPERIMENTAL
Intervention: Musicians' sera
Number of subjects: 40
Study 30059932 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-exposed controls (N=40)
Number of subjects: 40
Study 30060024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab with antibacterial drug treatment
Number of subjects: 0
Study 30060024 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial drug treatment alone (Control)
Number of subjects: 0
Study 30060061 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3039478 (oral dose: 2.5-100 mg, thrice weekly on a 28-day cycle)
Number of subjects: 110
Study 30060061 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3039478 (oral dose: 45-100 mg)
Number of subjects: 110
Study 30060061 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3039478
Number of subjects: 110
Study 30060083 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR) given for six cycles at standard doses
Number of subjects: 60
Study 30060083 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (800 mg daily continuously) in combination with bendamustine-rituximab (BR)
Number of subjects: 60
Study 30060328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism treatment
Number of subjects: 0
Study 30060328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypothyroidism treatment)
Number of subjects: 0
Study 30060751 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid point of care testing (POCT) for Neisseria meningitidis DNA
Number of subjects: 300
Study 30060751 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid point of care testing (POCT) for Procalcitonin (PCT)
Number of subjects: 300
Study 30060751 — intervention group
Group type: COMPARATOR
Intervention: Existing clinical practice guidelines (CPG) for feverish children with non-blanching rash
Number of subjects: 300
Study 30060751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of available diagnostic testing strategies
Number of subjects: 300
Study 30060751 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative methodology exploring views of families and clinicians
Number of subjects: 300
Study 30060751 — intervention group
Group type: EXPERIMENTAL
Intervention: Aetiology of non-blanching rashes (NBRs) in children with feverish illness
Number of subjects: 300
Study 30061026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine Hesitancy Scale (VHS) survey tool
Number of subjects: 720